top of page
A business meeting
Pharmaeconomica's Innovative Partnership Opportunities

Step into the world of innovation with Pharmaeconomica. Our current projects are on the cutting edge of pharmaceutical research, and we're inviting you to join us in shaping the future of healthcare through partnerships. From AI-driven drug discovery to groundbreaking diagnostics and therapies, our projects are opportunities for collaboration that can redefine healthcare. Let's accelerate discoveries and improve lives together. Explore our projects and be part of the future of healthcare.

Peptide-Based Lateral Flow Assay (LFA) for Alzheimer's Disease Diagnosis

  • Tackling a Global Challenge: Our research focuses on early and precise Alzheimer's disease (AD) diagnosis, addressing the significant hurdles of underdetection and delayed intervention.

  • Innovative Approach: We pioneer the use of blood-based biomarkers (BBB) for AD diagnosis, offering a cost-effective, non-invasive solution to complement existing methods, significantly improving early detection, primary care, and precision medicine for AD.

  • Comprehensive Assessment: We broaden diagnostic assays to encompass a range of AD-related proteins, ensuring a holistic diagnostic solution that recognizes AD's diverse nature.

  • Advanced Peptide Science: Leveraging advanced peptide science, we design peptides that bind precisely to AD-related proteins. These peptides are scalable for large-scale diagnostics, playing a crucial role in multiplex Lateral Flow Assays (LFA) capable of detecting multiple AD biomarkers in a single sample.

  • A Beacon of Hope: Our project represents more than just research; it's a beacon of hope for the millions affected by Alzheimer's. Together, we can make a meaningful impact and change the course of AD, offering hope and improved disease detection and management.

  • Join Us on the Journey: We invite you to join us on this journey to revolutionize AD diagnosis. Together, we can make a significant and positive difference in disease detection and management.

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
alzheimer pareja.png

Development of Effective Malaria Vaccines: Comprehensive Framework for In-silico Design of Peptide Vaccines against Crucial Plasmodium falciparum Targets

Malaria Stats

  • Global Risk: Almost half the world's population is at risk.

  • Cases: 247 million worldwide in 2021.

  • Deaths: Estimated 619,000 in 2021.

  • WHO African Region: 95% of cases and deaths.

  • High-Risk Groups: Children under 5 account for 80% of deaths.

  • Disease Burden: 2.6% of the global disease burden.

  • Costs: At least US $12 billion per year.

Unmet Needs

  • Resistance: Insecticide resistance among Anopheles mosquitoes.

  • Vulnerable Populations: Young children, pregnant women, travelers.

  • Artemisinin Resistance: WHO is very concerned about recent reports of partial artemisinin resistance in Africa, confirmed in Eritrea, Rwanda, and Uganda.

Challenges to Developing a Malaria Vaccine

  • Technical complexity in targeting a parasite.

  • Immune response to malaria infection is still incomplete.

  • Exposure to malaria does not confer lifelong protection.

  • The current malaria vaccine is limited, preventing just 30% of severe cases, leaving many children at risk.

Malaria Vaccine Project

  • Goal: Develop peptide vaccines against Plasmodium falciparum, the deadliest malaria parasite.

  • Approach: Use advanced bioinformatics and computational biology.

  • Target Proteins: Focus on eight critical proteins to disrupt the parasite's life cycle.

  • Vaccine Strategy: In-silico peptide approach for cross-species protection.

  • Timeline: Estimated 10 months per targeted vaccine.

  • Deliverables: In-vitro validated peptide candidates.

  • Impact: Potential to revolutionize malaria control.

bottom of page